Roger Léger

Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^

Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^

Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^

Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^

Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^